thyssenkrupp nucera (NCH2) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
17 Jun, 2025Management and company overview
Leadership team includes CEO with 20+ years in chemicals, CFO with 30 years industry experience, and CTO with 30 years in electrolysis.
Operates globally with a workforce of about 950 employees and a strong customer network.
Shareholder structure: thyssenkrupp 50.19%, De Nora 25.85%, Free Float 17.96%, others 6%.
Business model, products, and market position
Global provider of Alkaline Water Electrolysis (AWE) and Chlor-Alkali (CA) technologies.
Holds ~50% market share in core segments and is a market leader.
Delivered over 600 electrochemical projects and achieved 70% group sales growth in FY 22/23.
Order backlog as of June 2024: ~€0.9bn (AWE) and ~€0.4bn (CA).
Major customers include Covestro, BASF, Olin, H2 Green Steel, and Shell.
Financial performance and growth
FY 22/23 sales: €330mn (CA), €323mn (AWE); AWE sales up more than 6x year-over-year.
Q3 2023/24 sales reached €236mn, highest ever quarterly sales, with 26% year-over-year growth.
9M 2023/24 sales up 24% year-over-year to €612mn; AWE order intake up 78% year-over-year.
EBIT declined due to lower gross margin and higher ramp-up costs for AWE, as planned.
Net financial assets at €694mn as of June 2024.
Latest events from thyssenkrupp nucera
- Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update18 Mar 2026 - Strong financials, strategic innovation, and all agenda items approved amid market challenges.NCH2
AGM 202625 Feb 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 202513 Feb 2026 - Sales and EBIT declined sharply, but full-year guidance and order momentum remain strong.NCH2
Q1 202611 Feb 2026 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 20241 Feb 2026 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 202411 Jan 2026 - Record Q1 sales and EBIT growth, with strong outlook and robust order backlog.NCH2
Q1 202523 Dec 2025 - Q3 sales fell, but raised guidance and margin gains highlight improved outlook.NCH2
Q3 202523 Nov 2025 - Sales and EBIT rose 31% YoY, with strong project execution and guidance confirmed.NCH2
Q2 202519 Nov 2025